NEW YORK — Cancer Genetics on Thursday posted a nearly 24 percent year-over-year decline in revenues for the third quarter as the SARS-CoV-2 pandemic impacted its customers' R&D operations.
For the three-month period ended September 30, Cancer Genetics' revenues fell to $1.6 million from $2.1 million a year earlier as customers for its drug-discovery and preclinical oncology services experienced shifted their resources to SARS-CoV-2 initiatives and their scientific and discovery teams began working remotely.